Project Grant F30EY036720
- This Project Grant award of $423,767 from the National Eye Institute (CFDA 93.867 - Vision Research) supports research at the University of California, Davis focused on understanding the role of myeloid cells in glaucoma-related axonal degeneration. The project aims to determine whether NAD+-based interventions can protect retinal ganglion cell axons in a glaucoma-relevant model of axon injury, and to characterize the associated immune response. The research will leverage novel axon injury...
- This $460,625 Project Grant was awarded by the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) to Yale University. The grant will fund research to investigate the cellular and synaptic mechanisms underlying changes in retinal ganglion cell (RGC) activity following optic nerve injuries in mouse models of glaucoma. Specifically, the project aims to (1) determine the underlying mechanisms for altered RGC activity after increased intraocular pressure or...
- This $695,018 federal project grant awarded by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports research to define how Müller glia (MG) cells, which function as injury-responsive stem cells, can enable retinal regeneration in zebrafish, mice, and potentially humans. The research aims to identify genes that regulate the regenerative potential of MG cells in the context of selective retinal cell loss, as occurs in degenerative eye diseases. By conducting...
- This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides funding to Human Cell Co, a for-profit biotechnology research company, to develop a combination therapy for glaucoma. The award, totaling $360,897, will support research to determine if topical application of a nerve growth factor (NGF) mutein (HC201) in combination with oral nicotinamide (NAM) supplementation can more effectively improve retinal ganglion cell function compared to either treatment...
- This Project Grant award for $679,159 from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports research on in vivo epigenetic reprogramming of retinal ganglion cells (RGCs) in aging mice with glaucoma. The research aims to identify new therapeutic targets for glaucoma that can protect and rejuvenate RGCs, which are specifically targeted and damaged in this disease leading to vision loss. The 4-year project, awarded to The Schepens Eye...
- The National Eye Institute (NEI) awarded a $451,000 Project Grant under the Vision Research federal grant program (CFDA 93.867) to The Regents of the University of California, San Francisco (UCSF) to conduct a multimodal characterization of a novel inherited mouse model of glaucoma. The research aims to evaluate structural and functional changes in the mouse model, including axonal degeneration, retinal ganglion cell loss, dendritic changes, and neuroinflammatory responses. It will also identify...
- This Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) provides $393,008.00 to the University of California, Davis to conduct research on axonal regeneration in the frog Xenopus laevis. The goal is to systematically understand how this species successfully recovers from optic nerve injuries and regains vision, with the potential to translate these findings into therapies. Key activities include live imaging-based experiments to investigate the roles of the DLK and...
- The U.S. National Eye Institute (NEI) awarded a Project Grant under the Vision Research federal grant program (CFDA 93.867) to The Leland Stanford Junior University (Stanford University) in the amount of $257,785. The grant supports research to investigate the role of DNA damage response pathways, specifically the inhibition of checkpoint kinase 1 (CHK1), in enhancing retinal ganglion cell survival and promoting neuroprotection for the treatment of traumatic optic neuropathy (TON). The...
- This federal Project Grant award of $428,349 from the National Eye Institute's Vision Research program (CFDA 93.867) supports research into the mechanistic assessment of retinal ganglion cell genesis. The award, with a performance period from July 1, 2025 to March 31, 2030, aims to investigate the shared gene regulatory network and downstream targets of the key transcription factors Atoh7, Pou4f2, and Isl1 that are required for proper retinal ganglion cell development. The research will be...
- This federal Project Grant award of $764,881 from the National Eye Institute (CFDA 93.867 - Vision Research) supports research to investigate the role of advanced glycation end products (AGEs) in primary open-angle glaucoma (POAG). The overarching hypothesis is that the accumulation of AGEs in the trabecular meshwork promotes extracellular matrix remodeling and cell dysfunction, leading to increased outflow resistance and elevated intraocular pressure in POAG. The research project has two...
ELUCIDATING THE ROLE OF THE THOUSAND AND ONE KINASES IN RETINAL GANGLION CELL DEATH - ABSTRACT GLAUCOMA CAUSES IRREVERSIBLE, PROGRESSIVE VISION LOSS VIA AXON INJURY AND SUBSEQUENT CELL DEATH OF RETINAL GANGLION CELLS (RGCS). CURRENT TREATMENTS AIM TO LOWER INTRAOCULAR PRESSURE, ALTHOUGH THIS IS INSUFFICIENT IN SOME PATIENTS AND ASSOCIATED WITH COMPLICATIONS IN OTHERS. AS SUCH, IT IS PROPOSED HEREIN TO DEVELOP COMPLEMENTARY STRATEGIES TO MITIGATE AXON INJURY SIGNALING. FROM PREVIOUS HIGH-THROUGHPUT FUNCTIONAL GENOMIC SCREENS IN RGCS, DUAL LEUCINE ZIPPER KINASE (DLK) AND ITS PARALOG, LEUCINE ZIPPER KINASE (LZK), EMERGED AS CENTRAL PLAYERS IN THE CELL-AUTONOMOUS PATHWAY CAUSING CELL DEATH FOLLOWING AXON INJURY VIA UPSTREAM REGULATION OF JUN N-TERMINAL KINASE 1-3 (JNK1-3). DESPITE DLK/LZK'S ROLE AS MASTER REGULATORS OF RGC CELL DEATH FOLLOWING INJURY, THEIR REGULATION IS POORLY UNDERSTOOD. FURTHER INVESTIGATION OF DLK AND ITS INTERACTIONS HAS THE POTENTIAL TO REVEAL THE UPSTREAM REGULATORY MECHANISMS INVOLVED IN RGC DEATH AND THUS, ADDITIONAL THERAPEUTIC TARGETS. IN AN ADDITIONAL HIGH THROUGHPUT SCREEN OF THE ENTIRE KINOME IN MOUSE RGCS, THE THOUSAND AND ONE (TAO) KINASES, SPECIFICALLY TAOK1 AND TAOK2, SURFACED AS KEY MEDIATORS OF CELL DEATH. COMBINED KNOCKOUTS OF TAOK1 AND TAOK2 PROMOTED ROBUST AND SUSTAINED RGC SURVIVAL IN THE MOUSE OPTIC NERVE CRUSH (ONC) MODEL. THE CENTRAL HYPOTHESIS OF THIS PROPOSAL IS THAT TAOK1/2 WORK AS REGULATORS OF THE DLK/LZK/JNK SIGNALING AXIS AND MEDIATE NEURONAL CELL DEATH IN RESPONSE TO AXON INJURY. THIS HYPOTHESIS WILL BE STUDIED IN A RODENT MODEL AND IN HUMAN STEM CELL-DERIVED RGCS USING PHARMACOLOGICAL AND VIRAL-BASED TOOLS COMBINED WITH CRISPR/CAS9 GENE EDITING TO PRODUCE LOSS- AND GAIN-OF-FUNCTIONS. AIM 1 WILL ELUCIDATE THE RELATIONSHIP BETWEEN THE TAO KINASES AND DLK/LZK/JNK IN AXON INJURY SIGNALING, BY GENETICALLY PROBING THE UPSTREAM/DOWNSTREAM RELATIONSHIP OF THESE KEY KINASES IN VITRO AND IN VIVO IN MICE. AIM 2 WILL EXPLORE THE ROLE OF TAO KINASES IN CELL DEATH SIGNALING USING AN IN VITRO MODEL OF HUMAN RGCS. IF SUCCESSFUL, THE WORK PROPOSED HEREIN WILL SHED LIGHT ON THE ROLE OF THE TAO KINASES IN THE PATHWAY RESPONSIBLE FOR RGC DEATH IN A MOUSE MODEL AND IN HUMAN STEM CELL-DERIVED RGCS. THE NEUROPROTECTIVE POTENTIAL OF TAO KINASE INHIBITION HAS YET TO BE FULLY UNDERSTOOD AND COULD BE LEVERAGED TO MITIGATE RGC DEATH AND VISION LOSS IN GLAUCOMA. FURTHERMORE, WITH THE COMPLETION OF AIM 1, THE PRINCIPAL INVESTIGATOR WILL ACQUIRE NEW SKILLS IN ADENOVIRUS AND AAV PRODUCTION, HISTOLOGICAL AND FUNCTIONAL MEASURES OF RGC NEUROPROTECTION, AND VIRAL/CRISPR-BASED APPROACHES TO MANIPULATING GENE FUNCTION. WITH THE COMPLETION OF AIM 2, THE PRINCIPAL INVESTIGATOR WILL ACQUIRE NEW SKILLS IN HUMAN STEM CELL CULTURE AND RNA SEQUENCING. THE PRINCIPAL INVESTIGATOR WILL GREATLY BENEFIT FROM WORKING UNDER THE DIRECT SUPERVISION OF THE SPONSOR ON THIS PROPOSAL, DR. DEREK WELSBIE, AN EXPERT IN GLAUCOMA AND DLK/LZK SIGNALING, AND THE CO-SPONSOR, DR. KARL WAHLIN, AN EXPERT IN THE DIRECTED DIFFERENTIATION OF STEM CELLS INTO RETINAL TISSUE. ADVISEMENT FROM A COMMITTEE OF EXPERTS IN THE FIELD, CONTINUED COURSEWORK AND ACCESS TO CORE FACILITIES AT UC SAN DIEGO WILL ALSO BE A BOON TO HIS TRAINING AND EFFORTS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $42.3k | 4/23/25 | ||
| Not listed | $42.3k | 4/23/25 | ||
| Not listed | $0 | 4/23/25 |